Placeholder Banner

NCATS R&D Day Aimed At Linking Investors to Preclinical Drug Development Projects

September 9, 2013
On behalf of the National Center for Advancing Translational Sciences (NCATS), I invite BIO stakeholders to join us for our inaugural “Research & Development Day” September 12 in Cambridge, Mass. Novartis Institutes for Biomedical Research will host the event at which researchers will showcase therapeutic candidates for indications such as sickle cell disease, hereditary inclusion body myopathy, Duchenne muscular dystrophy and cryptococcal meningitis to potential partners. To register and view the agenda, visit

[caption id="attachment_12814" align="alignright" width="145"]John McKew, Acting Scientific Director, Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences John McKew[/caption]

The day will include opportunities for participants to learn more about opportunities to collaborate and adopt preclinical drug development projects currently supported by NCATS’ Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs) programs. The goal of both programs is to advance and de-risk preclinical projects to the stage where they can attract third-party investors.

As projects mature and are adopted from TRND and BrIDGs, NCATS also seeks new promising preclinical candidates. Currently, TRND is accepting proposals for collaborative projects requiring preclinical support. Academics, small and large companies, and foundations may apply. Letters of intent are due by September 16, 2013, and final proposals are due on September 30, 2013. Visit Apply to TRND to get started. And, NCATS will begin accepting proposals between January and February 2014 to participate in the BrIDGs program.

A key aspect of the NCATS mission is to play an adaptor role, bridging the translational gap between basic research discoveries and development of interventions that tangibly improve human health. To facilitate this process, NCATS relies on strategic partners to complete the final phases of clinical development. My colleagues and I hope to see you in September!

For more information at NCATS and its programs, visit

John McKew is the Acting Scientific Director, Division of Pre-Clinical Innovation, at the National Center for Advancing Translational Sciences.